1. 1. Xu, Q, Zhang X, Zou Y (2020) Primitive ovarian carcinosarcoma: a clinical and radiological analysis of five cases. J Ovarian Res, 13(1): 129. [ DOI:10.1186/s13048-020-00728-2] 2. Gauci M and J Calleja-Agius (2024) Spotlight on carcinosarcoma of the ovary: A scoping review. Acta Medica (Hradec Kralove), 67(1): 1-11. [ DOI:10.14712/18059694.2024.13] 3. Zhu L, Lu W, Wang F, Wang Y, Wu P-Y, Zhou J, Liu H (2023) Study of T2 mapping in quantifying and discriminating uterine lesions under different magnetic field strengths: 1.5 T vs. 3.0 T. BMC Med Imaging, 23(1): 1. 4. Ismail A, Choi S, Boussios S (2023) Frontiers of ovarian carcinosarcoma. Curr Treat Options Oncol, 24(12): 1667-1682. [ DOI:10.1007/s11864-023-01138-4] 5. Jin X, Zhu P, Fan Sh, Dai J (2023) Magnetic resonance imaging for the diagnosis of malignant mixed Mullerian tumor of ovary: Two case reports. Medicine (Baltimore), 102(50): e36569. [ DOI:10.1097/MD.0000000000036569] 6. Liu S, Peng M, Yu R, Jin C, Zhou Sh, Deng Y, Zhao D (2025) Predictive value of MR imaging IVIM and T2 mapping in malignant transformation of endometriosis. Medicine (Baltimore), 104(51): e46665. [ DOI:10.1097/MD.0000000000046665] 7. Hollis RL, Croy I, Churchman M, Bartos C, Rye T, Gourley Ch, Herrington CS (2022) Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma. Br J Cancer, 127(6): 1034-1042. [ DOI:10.1038/s41416-022-01874-8] 8. Belbaraka R, Taleb A, Errihani H (2010) A rare tumor of the ovary: Carcinosarcoma. Journal of Medical Cases, 1(2): 55-57. [ DOI:10.4021/jmc1w] 9. Gagliardi T, Adejolu M, de Souza NM (2022) Diffusion-weighted magnetic resonance imaging in ovarian cancer: Exploiting strengths and understanding limitations. J Clin Med, 11(6): 1524. [ DOI:10.3390/jcm11061524] 10. Zheng J, et al. (2023) Carcinosarcoma of the ovary: A case report and literature review. Front Oncol, 13: 1278300. [ DOI:10.3389/fonc.2023.1278300] 11. Chu W and Huang D (2026) Pyroptosis-related gene signatures in ovarian cancer treatment follow-up using MRI. Int J Radiat Res, 24(1): 9-16. [ DOI:10.66224/ijrr.24.1.2] 12. Liu R, et al. (2022) Apparent diffusion coefficient histogram analysis for differentiating solid ovarian tumors. Front Oncol, 12: 904323. [ DOI:10.3389/fonc.2022.904323] 13. Lu X, Xie S, Mou D, Peng M (2025) Relationship between MRI imaging characteristics and serum markers CEA, CA199, CA125 levels in ovarian cancer patients. Int J Radiat Res, 23(3): p. 513-519. [ DOI:10.61882/ijrr.23.3.1] 14. Matsuura Y, Kitajima M, Hachisuga T, Tanimoto A, Okura N, Kihara I (2010) Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings. J Obstet Gynaecol Res, 36(4): 907-11. [ DOI:10.1111/j.1447-0756.2010.01238.x] 15. Sit AS, Price FV, Kelley JL, Comerci JT, Kunschner AJ, Kanbour-Shakir A, Edwards RP (2000) Chemotherapy for malignant mixed Müllerian tumors of the ovary. Gynecol Oncol, 79(2): 196-200. [ DOI:10.1006/gyno.2000.5956] 16. Carter JS, Koopmeiners JS, Kuehn-Hajder JE, Metzger GJ, Lakkadi N, Downs Jr LS, Bolan PJ (2013) Quantitative multiparametric MRI of ovarian cancer. J Magn Reson Imaging, 38(6): 1501-9. [ DOI:10.1002/jmri.24119]
|